December 11, 2024
Enhanced TwinRCT™ 3.0
Unlearn® has introduced an upgraded version of its AI-driven TwinRCT™ solution—TwinRCT 3.0, aimed at significantly optimizing Phase 2 clinical trials. By using digital twins—AI-generated, data-based projections of individual patient outcomes—the technology allows trials to reach higher statistical power without increasing the number of participants. This approach addresses the costs and delays typically associated with expanding trial cohorts.
Boosting Statistical Power in Phase 2 Trials
TwinRCT 3.0 now incorporates data from previous clinical trials, enhancing its performance in Phase 2—the critical stage that often determines whether a drug progresses to Phase 3. Unlike traditional methods, which require larger participant pools to boost statistical significance, TwinRCT leverages AI to simulate outcomes. This results in more efficient, accurate, and faster trial execution.
Case Study Illustrates Efficiency Gains
A case study involving an Alzheimer’s Disease trial highlights the potential of TwinRCT. The analysis showed that Unlearn’s latest version could have achieved the same statistical power using 23% fewer participants, which would have also eliminated a 5-month delay in recruitment.
TrialPioneer Platform Integration
TwinRCT 3.0 is now integrated into Unlearn’s TrialPioneer platform—a free, web-based tool designed for pharmaceutical and biotech companies to collaborate, evaluate trial designs, and analyze their impact on sample size, statistical power, and enrollment timelines. Supporting trials for seven major diseases—including Alzheimer’s, ALS, and Parkinson’s—TrialPioneer is poised to transform how clinical trials are conceptualized and conducted across the industry.
Revolutionizing Clinical Trials with AI
With its cutting-edge AI-powered tools, Unlearn is reshaping clinical research by accelerating trial timelines and helping bring new treatments to patients more efficiently.
About Unlearn AI
Unlearn is at the forefront of clinical research innovation through the use of AI-generated digital twins. Its solutions enable pharmaceutical and biotech companies to conduct streamlined, data-driven trials with improved decision-making. Recognized by global regulatory agencies, Unlearn’s technology aligns with FDA guidance and is EMA-qualified for Phase 3 clinical trials. Unlearn AI News
By
